Sponsored

Meet Dr Sara Hurvitz – the latest addition to Radiopharm Theranostics’ (ASX:RAD) SAB

Highlights

  • ASX-listed clinical-stage radiotherapeutics firm Radiopharm Theranostics has engaged Sara Hurvitz MD as a member of its Scientific Advisory Board (SAB).
  • RAD is a leading developer of radiopharmaceutical products for both diagnostic and therapeutic uses.
  • Dr Hurvitz joins Dr Johannes Notni, Professor Eric Aboagye, Dr David Ulmert and Dr Hong Hoi Ting on the SAB.
  • Radiopharm’s SAB is chaired by firm’s Chief Medical Officer Professor David Mozley.

The ASX-listed clinical-stage radiotherapeutics company, Radiopharm Theranostics Limited (ASX:RAD), has reinforced its Scientific Advisory Board (SAB) with the appointment of Dr. Sara Hurvitz MD.  Radiopharm Theranostics is engaged in the development of top-class radiopharmaceutical products for both diagnostic and therapeutic uses.

Dr Hurvitz joins Dr Johannes Notni, Professor Eric Aboagye, Dr David Ulmert and Dr Hong Hoi Ting on the SAB, which is chaired by Radiopharm’s Chief Medical Officer Professor David Mozley.

Dr Hurvitz’s appointment is expected to give a massive boost to development of the company’s radiopharmaceutical pipeline.

Must read: Radiopharm Theranostics debuts on the ASX, raises AU$50M via IPO 

A snapshot of Dr. Sara Hurvitz’s profile

Addition of a new profile

Image source: © Andreyyalansky19 | Megapixl.com

With expertise in breast cancer treatment, Dr Hurvitz holds an extensive clinical and translational research portfolio. Dr Hurvitz is involved in designing, implementing, and leading clinical trials to test new targeted therapies. This includes studies of the gene expression patterns in several breast cancer populations and analysing these patterns to detect novel subtypes of breast cancer which new therapies are likely to target more accurately.

Dr Hurvitz dons several hats as she serves as the director of the Breast Oncology Program at UCLA’s Division of Hematology-Oncology, Medical Director of Jonsson Comprehensive Cancer Center’s Clinical Research Unit at UCLA, co-director of the Santa Monica-UCLA Outpatient Oncology Practice, and Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).

She is also a member of the American Association of Cancer Research and the American Society of Clinical Oncology. She is a fellow of the American College of Physicians.

She has been honoured with several awards including the Marine Levine Memorial Breast Cancer Research Award from 2008 through 2015.

You may read: Why is Radiopharm (ASX:RAD) attracting investors’ attention?

Dr Hurvitz an ‘invaluable’ addition

Speaking about Dr Hurvitz’s appointment to the SAB, Radiopharm Theranostics Managing Director and CEO Riccardo Canevari said,

“We are thrilled to have Dr Hurvitz join our highly experienced Scientific Advisory Board. Her wealth of expertise and thought leadership in cancer treatment will prove invaluable as we continue the development of our radiopharmaceutical products.”

Stock information: On 7 December 2021 RAD shares traded at AU$0.300 on the Australian Securities Exchange (ASX), with market capital of AU$78.53 million.

Related article: Radiopharm Theranostics debuts on the ASX, raises AU$50M via IPO  

Also read: Top ASX-listed oncology stocks to look at in 2022

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK